Compare McDonald's Corp (MCD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Twist Bioscience Corp — how do they compare? McDonald's Corp trades at $236.79 (market cap $163.38B), while Twist Bioscience Corp trades at $157 (market cap $10.08B). The key difference: McDonald's Corp is far larger — about 16.2× Twist Bioscience Corp's market cap, and McDonald's Corp pays a 3.34% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and Twist Bioscience Corp for 27 Days on average.
| MCD | TWST | |
|---|---|---|
Market Cap | $163.38B | $10.08B |
Volume | 4,647,229 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $205.00 |
52-Week Low | $230.88 | $25.45 |
Typical Hold Time | 164 Days | 27 Days |
Enterprise Value | $217.15B | $10.01B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $236.9, up 1.91% for the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $26.89B and net income of $8.56B, supported by a 57.38% gross margin. Recent news highlights a new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $286.95 price target, but technical indicators and macroeconomic headwinds pose risks. Investment opportunity lies in McDonald's resilient franchise model and dividend yield, though inflation and execution of new initiatives are key watchpoints for shareholders.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
